Drug that does not fulfill promises

A drug released in January as a major breakthrough in the treatment of Govt-19 by the Montreal Heart Institute is far from fulfilling its promises.

Read more: Python management is doubling down on buying Pfizer’s anti-Govit-19 pill

Read more: Health Canada warns against preparation for sexual performance

Read more: Israel receives first export of anti-Govt pills

Almost a year later, the use of colchicine is no longer in the arsenal of treatment to fight the corona virus. And the situation is not going to change.

“We have given hope to the planet!”

Controversies

Since then, scientific ideas have grown around the world to question the effectiveness of the drug.

• The National Institutes of Health and Social Services (INESSS), responsible for evaluating the benefits of drugs in Quebec, have intervened on two occasions to advise against their use.
• In October, Science Journal The Lancet Published the final results of a major British study concluding that colchicine was ineffective in the treatment of Govit-19.
• The final results of the Heart Institute’s study, published a few months after the January announcement, concluded that they were not significant.

Dr. Dartiff and the Heart Institute are quiet now.

We have not been able to get feedback from those who have repeatedly requested our intelligence unit.

We tried to approach all seven researchers who were part of the scientific team overseeing Colkis’ study without receiving a response from them.

However, expectations were high at the onset of the epidemic, and the company and Dr. Dartiff announced that they would be conducting a study on colchicine.

Quebec Involvement

Prime Minister François Legault was invited to recruit study participants during his prestigious daily press conferences. The Quebec government also contributed $ 5 million.

In January 2021, the publication of preliminary results of clinical trials by the Heart Institute suggested a huge success, with the Canadian and international media immediately capturing it.

The company’s successful press release is referred to as a “major scientific discovery”.

But, in May, the final results of a similar study were released The Lancet, But this method was edited by a team of external scientists, revealing a very different picture.

Marketing

Therefore, if all participants in clinical trials are taken into account, the results are “not statistically significant”.

We highly recommend The Lancet To conduct new studies to confirm the positive effects on some of the participants recruited by the Heart Institute.

“This is the problem with journalism,” said Professor Joe Swarks, president of the Organization for Science and Community, affiliated with McGill University.

“The field of research has become very competitive and everyone is trying to make an invention first. So everyone wants to mark their territory. It becomes a question of marketing.”

Physicians are critical of this approach

In medical circles in Quebec, Dr. The manner in which Jean-Claude Dordiff and the Heart Institute did raised pessimism and many questions.

“When [le communiqué initial sur l’étude] Published, I do not understand, I was shocked, “said Dr. Michael de Marci, a physician in the intensive care unit of a Jewish hospital in Montreal.

“If the best anti-inflammatory drugs, steroids, have a mixed effect on covit, we may think that colchicine is unlikely to be effective (as anti-inflammatory),” says the serious expert who has to deal with it. Several COVID-19 cases since the onset of the infection.

False good news

His colleague Dr. from the intensive care unit at Hôpital Maisonneuve-Rosemont. Franுவாois Marquis adds: “When we want to go too fast, we sometimes get the wrong gospel. It will happen, it is a shame. “

Dr. Marquis, especially in an epidemic context, strongly condemns this way of exaggerating the results because of the expectations it can create.

“It simply came to our notice then [au sujet de la COVID-19] Sadly confused people. “

Another treatment works much better

Unlike colchicine, Pfizer’s new antiviral, Paxlovit, was approved by US authorities before the holidays for vulnerable people, which has a clear impact on reducing complications from COVID-19. Here’s how the two drugs differ. *

* This comparison was verified with a reliable scientific source.

⁇ Colchicine

• Two out of 10 people with Covit-19 are hospitalized or prevent death
• The Heart Institute medical study has been completed for almost a year and colchicine has not yet been recommended as a proper treatment.
• The common property of colchicine is to use its anti-inflammatory effects to reduce the effects of Govit-19.

⁇ Paxlovit

• Nine out of 10 people with Covit-19 are hospitalized or prevented from dying
• The antiviral drug was submitted to the US government for approval before the end of its clinical trial
• Designed with the exclusive operation mechanism specific to Covit-19

He is quietly testing another drug

Dr. who is very active in research. Jean-Claude Dordif also conducted another clinical study on the effects of the drug tolcetropine to reduce the complications of Govit-19. The study was funded by DalCor, which included Dr. Tardif is a partner with the wealthy Desmarais family. According to the reference site Clinicaltrial.gov, the clinical trials were completed in May, but no results have yet been filtered before the holiday.

We could not get the reasons for this delay as we have repeatedly requested DalCor and Dr Tardif.

Discovery Deflates

The final results have been released The Lancet

In a scientific publication where final results are presented after being reviewed by external experts, the results for all participants are “not statistically significant”. The key finding becomes the recommendation for new tests to test the effectiveness of colchicine.

Heart Institute Press Release

The results for all patients in the study are presented in ambiguous terms. They are said to be approaching “statistical significance”. In addition, by removing the results of some participants (See the text on the right), The company did not hesitate to talk about a “major scientific discovery”.

There were 329 participants Was excluded from the study

To claim success, the Heart Institute withdrew the results of 329 of the 4,488 people who participated in its clinical study. These people have symptoms of COVID-19, but due to the lack of tests at the onset of infections, unlike other participants, the diagnosis could not be confirmed by testing. With this withdrawal, the effects of colchicine are measurable, but limited. However, evaluating the results of the study as a whole, i.e. with 4488 participants, had only the effect of colchicine “not being statistically significant”. The Lancet, On the problems of Govt-19.

So she firmly believed that she would take it

Philanthropist Sophie Desmeres, who is said to be the leading sponsor of the Heart Institute study, is very confident about the effectiveness of colchicine and would not hesitate to take it if she had COVID-19.

“The first thing I need to do: I will take colchicine,” he said in an interview.

Resistance

Ms. Desmeriz believes that Kolkisin is subject to opposition from governments and pharmaceutical companies.

“Because colchicine is a cheap generic drug […], Governments and pharmaceutical companies are not interested in helping us because there is no money for them, ”he says.

Mrs. Desmaris donated $ 1 million from his pocket for the study. Other key supporters are the Quebec government ($ 5.3 million) and the Bill & Melinda Gates Foundation ($ 3 million).

See also